Thyroid dysfunction in antiviral therapy of chronic hepatitis C

Hepato-Gastroenterology

Volumn 57, Issue 101, 2010, Pages 826-831

  Dabrowska, Magdalena M ^a   Panasiuk, Anatol ^a   Flisiak, Robert ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Anti thyroid auto antibodies; Chronic HCV infection; IFN therapy; Thyroid dysfunction

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC RISK; GENOTYPE; HEMATOLOGICAL PARAMETERS; HEPATITIS C; HUMAN; HYPOTHYROIDISM; LEUKOCYTE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; THYROID FUNCTION TEST; TREATMENT RESPONSE; VIRUS GENE;

ADULT; ANTIVIRAL AGENTS; AUTOANTIBODIES; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; HYPOTHYROIDISM; INTERFERON-ALPHA; MALE; MIDDLE AGED; THYROID FUNCTION TESTS; THYROID GLAND; YOUNG ADULT;

EID: 78149261885     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Available from: URL: http://www.who.int.
2. Backus LI, Boothroyd DB, Philips BR, Mole LA: Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46:37-47.
3. Pellicano R, Smedile A, Peyre S et al: Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view. Minerva Gastroenterol Dietol. 2005; 51:55-61.
4. Tomer Y, Blackard JT, Akeno N: Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am. 2007, 36:1051-1066.
5. Mandac JC, Chaudhry S, Sherman KE, Tomer Y: The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006, 43:661-672.
6. Dalgard O, Bjøro K, Helium K et al: Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med. 2002; 251:400-406.
7. Murakami M, Kakizaki S, Takayama H, Takagi H, Mori M: Autoimmune thyroid disease induced by interferon therapy. Nippon Rinsho. 1999; 57:1779-1783.
8. Tran HA, Jones TL, Batey RG: The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin. BMC Endocr Disord. 2005; 12:8.
9. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E: Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004; 89:3656-3661.
10. Wang SH, Bretz JD, Phelps E et al: A unique combination of inflammatory cytokines enhances apoptosis of thyroid follicular cells and transforms nondestructive to destructive thyroiditis in experimental autoimmune thyroiditis. J Immunol. 2002; 168:2470-2474.
11. Kee KM, Lee CM, Wang JH et al: Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. J Gastroeneterol Hepatol. 2006; 21:319-326.
12. Doi F, Kakizaki S, Takagi H et al: Long-term outcome of interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C. Liver Int. 2005; 25:242-246.
13. Scheuer PJ, Davies SE, Dhillon AP: Histopathological aspects of viral hepatitis. J Viral Hepat. 1996; 3:277-283.
14. Antonelli A, Ferri C, Pampana A et al: Thyroid disorders in chronic hepatitis C. Am J Med. 2004; 117:10-13.
15. Quaranta IF, Tran A, Regnier D: High prevalence of auto-antibodies to hepatitis-C virus (HCV) in patients with anti-thyroid auto-antibodies (letter). J Hepatol. 1993; 18:136.
16. Hsieh MC, Yu ML, Chuang WL et al: Virologic factors related to interferon-α-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol. 2000; 142:431-437.
17. Baudin E, Marcellin P, Pouteau M et al: Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol. 1993; 39:657-661.
18. Pateron D, Augiar J, Duclos-Valle JC, Jouanolle H, Hartman DJ, Beaugrand M: High prevalence of abnormal thyroid test in patients with chronic hepatitis C (CHC) before alpha interferon (INF) therapy: relation with INF induced thyroid dysfunction. Hepatology 1991; 14:77.
19. Marazuela M, Garcia-Buey L, Gonzalez-Fernandez B et al: Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon alpha therapy. Clin Endocrinol. 1996; 44: 635-642.
20. Huang JF, Chuang WL, Dai CY et al: The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferone-alpha and ribavirin combination therapy. J Viral Hepat. 2006; 13:396-401.
21. Russo MW, Fred MW: Side effects of therapy for chronic hepatitis C. Gastroenterology 2003; 124:1711-1719. (Pubitemid 36617688)
22. Custro N, Montalto G, Scafidi V et al: Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest. 1997; 20:374-380.
23. Preziati D, La Rosa L, Covini G et al: Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol. 1993; 39:657-661.
24. Fernandez-Soto L, Gonzalez A, Escobar-Jimenez F et al: Increased risk of autoimmune thyroid disease in hepatitis C v. hepatitis B before, during and after discontinuing interferon therapy. Arch Intern Med. 1998; 158:1445-1448.
25. Oppenheim Y, Yoshiyuki B, Yaron T: Interferon induced Autoimmune Thyroid Disease (AITD); a model for human autoimmunity. Autoimmun Rev. 2004; 3:388-393.
26. Serafińska S, Smoliński P, Simon K et al: Thyroid dysfunction in pegylated-inteferon (Peg-IFNα) treated patients with chronic hepatitis C - a single center retrospective study. E&C Hepatology 2006; 2:52-54.
27. Tran HA, Attia JR, Jones TL, Batey RG: Pegylated interferon-α2B in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-α2β in a hepatitis C population: Meta-nalysis. J Gastroenterol. 2007; 22:472-476.
28. Malaguarnera M: A comparison of four types of interferon alpha in the treatment of chronic hepatitis C. Curr Ther Res. 1998; 59:48.
29. Fagiuoli S, Pevere S, Minniti F et al: Natural leukocyte interferon alpha for the treatment of chronic viral hepatitis in heart transplant recipients. Transplantation. 2003; 75:982-986.
30. Cerella C, Mazziotti G, Morsico F et al: The addition of ribavirin to interferon α therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. Eur J Endocrinol. 2002; 146:743-749.